The development of a novel dry powder inhaler

Abstract A novel active and multi-dose dry powder inhaler (DPI) was developed and evaluated to deliver a small quantity (100–500 μg) of pure drug without any excipient. This dry powder inhaler utilized two compressed air flows to dispense and deliver drug powder: the primary flow aerosolizes the drug powder from its pocket and the secondary flow further disperses the aerosol. In vitro tests by Anderson Cascade Impactor (ACI) indicated that the fine particle fraction (FPF) (